ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2512

A Qualitative Study of Clinicians’ Perspectives on Barriers to Implementation of Treat to Target in Psoriatic Arthritis

Julie Taylor 1, Laura Coates2 and Emma Dures 1, 1Department of Nursing and Midwifery, University of the West of England, Bristol and Academic Rheumatology, University Hospitals NHS Trust, Bristol, England, United Kingdom, 2University of Oxford, Oxford, United Kingdom

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Psoriatic arthritis, treatment guidlelines and qualitative

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: European League Against Rheumatism Treatment recommendations support implementing a treat-to-target (T2T) approach in psoriatic arthritis (PsA) based on the findings of the TICOPA trial. However, a UK survey estimated that ~90% of clinicians do not follow this. This study explored clinicians’ views on implementing T2T in PsA.

Methods: Individual interviews and a focus group with clinicians, audio-recorded and analysed using thematic analysis. Datasets were compared and integrated for analysis.

Results: Eight rheumatologists and two healthcare professionals (5-26 years’ experience) participated in telephone interviews (25-35 minutes). One consultant delivered PsA-specific clinics. Seven rheumatologists and two trainees (3-22 years’ experience) participated in a focus group (102 minutes). Three clinicians delivered PsA-specific clinics. There were four main themes: 

 

Individual motivation to change clinical practice: “We have set up weekly psoriatic arthritis clinics at our hospital and it took almost 2 ½ years.” Typically, individual clinicians with a specialist interest developed care pathways for PsA patients. They sought external information, training and support to champion T2T in their local service.  

 

A lack of consensus on what to measure: “There has to be a strong argument to get me to do any other type of assessment because PsARC is quicker and we’ve been trained appropriately.” Views varied on the assessments needed to inform disease management. A strong justification would be needed for measures that could increase appointment time and patient burden.

What is achievable with limited resources: “If it’s a mixed clinic it isn’t really that feasible”

Lack of nursing support and registrar training in skin/joint scores were barriers to T2T. Challenges were amplified when PsA patients attended general rheumatology clinics and there were no dedicated database systems to support data collection.

Mandatory versus voluntary pressures to change: “Actually knowing somebody’s watching you… with an audit makes a hell of a difference to how you run your service.” Changes in practice were more likely when mandated by service providers and linked to tariffs/funding. Sharing local guidelines and protocols could facilitate T2T implementation.

Conclusion: A driver of T2T implementation was clinicians with a specialist interest in PsA who set up dedicated clinics. Barriers included a lack of consensus about targets, and practical challenges (clinical time, collecting outcomes, insufficient training and database requirements). T2T implementation in PsA requires an integrated approach to address support and resource needs of individual clinicians, teams, local IT systems, and service providers.


Disclosure: J. Taylor, None; L. Coates, Abbvie, 2, 5, 8, AbbVie, 2, 5, 8, AbbVie, Amgen, BMS, Celgene Corporation, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Prothena, Sun Pharma, UCB, 5, Abbvie, Amgen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB, 5, Abbvie, Amgen, Lilly, Novartis, Pfizer, UCB, 8, AbbVie, Celgene Corporation, Eli Lilly, Janssen, Novartis, UCB, 8, AbbVie, Celgene Corporation, Eli Lilly, Novartis, Pfizer, 2, AbbVie, Celgene Corporation, Novartis, Pfizer, 2, Abbvie, Celgene, Novartis, Pfizer, Lilly, 2, Amgen, 5, 8, Biogen, 8, Bristol-Myers Squibb, 5, Celgene, 2, 5, 8, Eli Lilly, 2, 5, 8, Galapagos, 5, Gilead, 5, Janssen, 2, 5, 8, Janssen Research & Development, LLC, Lilly, 2, 5, 8, MSD, 5, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Pfizer Inc, 2, 5, 8, Prothena, 5, Sun Pharma, 5, UCB, 5, 8, UCB Pharma, 5; E. Dures, None.

To cite this abstract in AMA style:

Taylor J, Coates L, Dures E. A Qualitative Study of Clinicians’ Perspectives on Barriers to Implementation of Treat to Target in Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/a-qualitative-study-of-clinicians-perspectives-on-barriers-to-implementation-of-treat-to-target-in-psoriatic-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-qualitative-study-of-clinicians-perspectives-on-barriers-to-implementation-of-treat-to-target-in-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology